# US 2017/0320821 A1 · Novel aniline derivative, pharmaceutical composition containing same, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0320821 A1
- Document ID: US20170320821A1
- Status: Published application
- Kind: A1
- Application number: 15/659,760
- Filed: 2017-07-26
- Published: 2017-11-09
- Earliest claimed: 2014-02-28
- Assignees: Kissei Pharmaceutical Co., Ltd.
- Applicants: Kissei Pharmaceutical Co., Ltd.
- Inventors: Hitoshi Inoue; Kohsuke Ohno; Tetsuya Nakamura; Yusuke Ohsawa
- Web page: https://patentgrep.com/patent/US20170320821A1

## CPC

- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

[Problem] The present invention provides a novel compound having an S1P1 receptor antagonistic activity. [Solution] The present invention provides a compound represented by the general formula (I): (in the formula, Rl, R2 and R3 are each a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group or the like, R4 is a C1-6 alkyl group or the like, R5 is a C1-6 alkyl group or the like, R6 is a C1-6 alkyl group or the like, R7 is a hydrogen atom, a halogen atom, a C1-6 alkyl group or the like, R8 is a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, a C1-6 alkoxy group or the like, and R9 is a hydrogen atom or a C1-6 alkyl group.) or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same, and use thereof. The compounds of the present invention have an excellent S1P1 receptor antagonistic activity and therefore are useful as an agent for the treatment or prevention of antoimmune diseases and the like.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method of treating a disease mediated by S1P1 receptor in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound represented by the general formula (I):
wherein
R1, R2 and R3 are each independently any one of the following a) to f):
a) a hydrogen atom,
b) a halogen atom,
c) a C1-6 alkyl group,
d) a halo C1-6 alkyl group,
e) a C1-6 alkoxy, or
f) a cyano group;
R4 is any one of the following a) to f):
a) a C1-6 alkyl group,
b) a halo C1-6 alkyl group,
c) a cycloalkyl group,
d) a cycloalkyl C1-6 alkyl group,
e) a C1-6 alkoxy C1-6 alkyl group, or
f) a hydroxy C1-6 alkyl group;
R5 is any one of the following a) to c):
a) a hydrogen atom,
b) a C1-6 alkyl group, or
c) a hydroxy C1-6 alkyl group;
R6 is any one of the following a) to c):
a) a hydrogen atom,
b) a C1-6 alkyl group, or
c) a cyano group,
or R5 and R6 combine to form —(CH2)n-;
R7 and R8 are each independently any one of the following a) to h):
a) a hydrogen atom,
b) a halogen atom,
c) a C1-6 alkyl group,
d) a halo C1-6 alkyl group,
e) a C1-6 alkoxy group,
f) a hydroxy C1-6 alkyl group,
g) a C2-6 alkenyl group, or
h) a cyano group;
R9 is a hydrogen atom or a C1-6 alkyl group; and
n is 2 or 3,
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method as claimed in claim 17, wherein said subject is a human.

### Claim 19 (depends on 17)

The method as claimed in claim 17, wherein the compound is selected from the group consisting of:
1-(5-{1-[(4-Chloro-3-methylphenyl(ethyl)amino]ethyl}-2-methylbenzyl)-azetidine-3-carboxylic acid;
1-(5-{1-[(4-Chloro-3-trifluoromethylphenyl)(ethyl)amino]ethyl}-2-methylbenzyl)azetidine-3-carboxylic acid;
1-{1-[(4-Chloro-3-trifluoromethylphenyl)(ethyl)amino]-5-methylindan-4-ylmethyl}azetidine-3-carboxylic acid;
1-{1-[(4-Chloro-3-trifluoromethylphenyl)(methyl)amino]-5-methylindan-4-ylmethyl}azetidine-3-carboxylic acid;
1-(5-{1-[(4-Chloro-3-methylphenyl)(propyl)amino]ethyl}-2-methylbenzyl)-azetidine-3-carboxylic acid;
1-{1-[(4-Chloro-3-methylphenyl)(ethyl)amino]-5-fluoroindan-4-ylmethyl}-azetidine-3-carboxylic acid;
1-{1-[(4-Chloro-3-methylphenyl)(ethyl)amino]-5-methylindan-4-ylmethyl}-azetidine-3-carboxylic acid;
1-(5-{1-[(4-Chloro-3-trifluoromethylphenyl)(methyl)amino]ethyl }-2-methylbenzyl)azetidine-3-carboxylic acid;
1-(5-{1-[(4-Chloro-3-methylphenyl)(ethyl)amino]ethyl}-2-fluorobenzyl)-azetidine-3-carboxylic acid;
1-(2-Chloro-5-{1-[(4-chloro-3-methylphenyl)(ethyl)amino]ethyl}benzyl)-azetidine-3-carboxylic acid;
1-(2-Chloro-5-{1-[(4-chloro-3-trifluoromethylphenyl)(methyl)amino]ethyl}-benzyl)azetidine-3-carboxylic acid;
1-(2-Chloro-5-{1-[(4-chloro-3-trifluoromethylphenyl)(ethyl)amino]ethyl}-benzyl)azetidine-3-carboxylic acid;
1-(5-{1-[(4-Chloro-3-trifluoromethylphenyl)(ethyl)amino]ethyl}-2-trifluoromethylbenzyl)azetidine-3-carboxylic acid;
1-(5-{1-[(4-Chloro-3-methylphenyl)(ethyl)amino]ethyl }-2-trifluoromethyl-benzyl)azetidine-3-carboxylic acid;
1-(5-{1-[(4-Chloro-3-trifluoromethylphenyl)(ethyl)amino]propyl}-2-methyl-benzyl)azetidine-3-carboxylic acid; and
1-(5-{1-[(4-Chloro-3-methylphenyl)(ethyl)amino]propyl}-2-methylbenzyl)-azetidine-3-carboxylic acid;
or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 17)

The method as claimed in claim 17, wherein the disease mediated by S1P1 receptor is selected from the group consisting of autoimmune diseases, inflammatory bowel disease, age-related macular degeneration, acute or chronic rejection on allo- or xenogeneic tissue or organ transplantation, graft-versus-host disease and cancer.

### Claim 21

A method of treating a disease mediated by S1P1 receptor in a subject, said method comprising administering to said subject a therapeutically effective amount of 1-(5-{1-[(4-Chloro-3-trifluoromethylphenyl)(ethyl)amino]ethyl}-2-methylbenzyl)azetidine-3-carboxylic acid or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 21)

The method as claimed in claim 21, wherein said subject is a human.

### Claim 23 (depends on 21)

The method as claimed in claim 21, wherein the disease mediated by S1P1 receptor is selected from the group consisting of autoimmune diseases, inflammatory bowel disease, age-related macular degeneration, acute or chronic rejection on allo- or xenogeneic tissue or organ transplantation, graft-versus-host disease and cancer.

### Claim 24 (depends on 17)

The method as claimed in claim 17, wherein R7 and R8 are each independently any one of the following a) to g):
a) a hydrogen atom,
b) a halogen atom,
c) a C1-6 alkyl group,
d) a halo C1-6 alkyl group,
e) a C1-6 alkoxy group,
f) a hydroxy C1-6 alkyl group, or
g) a C2-6 alkenyl group.

### Claim 25 (depends on 17)

The method as claimed in claim 17, wherein R1, R2 and R3 are each independently any one of the following a) to e):
a) a hydrogen atom,
b) a halogen atom,
c) a C1-6 alkyl group,
d) a halo C1-6 alkyl group, or
e) a cyano group.

### Claim 26 (depends on 17)

The method as claimed in claim 17, wherein R4 is a C1-6 alkyl group or a hydroxy C1-6 alkyl group.

### Claim 27 (depends on 17)

The method as claimed in claim 17, wherein:
R5 is any one of the following a) to c):
a) a hydrogen atom,
b) a C1-6 alkyl group, or
c) a hydroxy C1-6 alkyl group, and
R6 is any one of the following a) to b):
a) a hydrogen atom, or
b) a C1-6 alkyl group,
or R5 and R6 combine to form —(CH2)n-.

### Claim 28 (depends on 17)

The method as claimed in claim 17, wherein R4 is a C1-6 alkyl group.

### Claim 29 (depends on 17)

The method as claimed in claim 17, wherein:
R7 is a hydrogen atom; and
R8 is any one of the following a) to f):
a) a halogen atom,
b) a C1-6 alkyl group,
c) a halo C1-6 alkyl group,
d) a C1-6 alkoxy group,
e) a hydroxy C1-6 alkyl group, or
f) a C2-6 alkenyl group.

### Claim 30 (depends on 17)

The method as claimed in claim 17, wherein:
R1 and R2 are each independently any one of the following a) to d):
a) a halogen atom,
b) a C1-6 alkyl group,
c) a halo C1-6 alkyl group, or
d) a cyano group; and
R3 is a hydrogen atom.

### Claim 31 (depends on 17)

The method as claimed in claim 17, wherein:
R5 is a C1-6 alkyl group, R6 is a hydrogen atom, or
R5 and R6 combine to form —(CH2)n-.

### Claim 32 (depends on 17)

The method as claimed in claim 17, wherein R1 and R2 are each independently any of the of the following a) to c):
a) a halogen atom,
b) a C1-6 alkyl group, or
c) a halo C1-6 alkyl group.

### Claim 33 (depends on 17)

The method as claimed in claim 17, wherein R8 is any one of the following a) to c):
a) a halogen atom,
b) a C1-6 alkyl group, or
c) a halo C1-6 alkyl group.

### Claim 34 (depends on 17)

The method as claimed in claim 17, wherein R9 is a hydrogen atom.

### Claim 35 (depends on 17)

The method as claimed in claim 17, wherein n is 2.
